Optimal glycemic control in the elderly: Where is the evidence and who should be targeted?

Aging Health

Volumn 7, Issue 1, 2011, Pages 89-96

  Tessier, Daniel M ^a  

^a UNIVERSITY INSTITUTE OF GERIATRICS OF SHERBROOKE   (Canada)

Author keywords

cognitive impairment; dementia; diabetes mellitus; elderly; hypoglycemia; pharmacology

Indexed keywords

APOLIPOPROTEIN E; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLICLAZIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

AGING; ALZHEIMER DISEASE; BLOOD PRESSURE REGULATION; CLINICAL FEATURE; CLINICAL RESEARCH; COGNITIVE DEFECT; COMORBIDITY; DEMENTIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE FREQUENCY; GENETIC ASSOCIATION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; KETOACIDOSIS; KIDNEY DISEASE; LIFE EXPECTANCY; MALAISE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PREVALENCE; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; STROKE;

EID: 79951750306     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/ahe.10.86     Document Type: Review

References (53)

1. Harris MI, Flegal KM, Cowie CC et al.: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21, 518-524 (1998). (Pubitemid 28172927)
2. DECODE study group, on behalf of the European Epidemiology Group: Glucose tolerances and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch. Intern. Med. 162, 397-405 (2001).
3. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43, 960-967 (1994). (Pubitemid 24230698)
4. Morisaki N, Watanabe S, Kobayashi J et al.: Diabetic control and progression of retinopathy in elderly patients: five-year follow-up study. J. Am. Geriatr. Soc. 42, 142-145 (1994). (Pubitemid 24057349)
5. Bertoni AG, Krop JS, Anderson GF, Brancati FL: Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care 25, 471-475 (2002). (Pubitemid 41103338)
6. Meneilly GS, Tessier D: Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can. J. Diabetes 32, S181-S186 (2008).
7. California Healthcare Foundation/American Geriatrics Society on Improving Care for Elders with Diabetes: guidelines for improving the care of the older person with diabetes mellitus. J. Am. Geriatr. Soc. 51, S265-S280 (2003).
8. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 352, 837-853 (1998).
9. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR: 10-year follow-up of intensive glucose control in Type 2 diabetes. N. Engl. J. Med. 359, 1577-1589 (2008).
10. The Action of Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008).
11. The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med. 358, 2560-2572 (2008).
12. Duckworth W, Abraira C, Moritz T et al.: Glucose control and vascular complications in veterans with Type 2 diabetes. N. Engl. J. Med. 360, 129-139 (2009).
13. Bonds DE, Miller ME, Bergenstal RM et al.: The association between symptomatic, severe hypoglycaemia and mortality in Type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 339, 4909-4918 (2009).
14. Turnbull FM, Abraira C, Anderson RJ et al.: Intensive glucose control and macrovascular outcomes in Type 2 diabetes. Diabetologia 52, 2288-2298 (2009).
15. Akalin S, Berntorp K, Ceriello A et al.: Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control. Int. J. Clin. Pract. 63, 1421-1425 (2009).
16. Schernthaner G, Ritz E, Schernthaner G-H: Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly? Nephrol. Dial. Transplant. 25, 2044-2046 (2010).
17. Jee SJ, Lindquist MS, Segal MR, Covinski KE: Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 295, 801-808 (2006). (Pubitemid 43244307)
18. Greco D, Pisciotta M, Gambina F, Maggio F: Severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients aged 80 years or older. Exp. Clin. Endocrinol. Diabetes 118, 215-219 (2010).
19. Shorr RI, Ray WA, Daugherty JR, Griffin MR.: Incidence and risk factors for serious hypoglycaemia in older persons using insulin or sulfonylureas. Arch. Int. Med. 157, 1681-1686 (1997). (Pubitemid 27327403)
20. Shorr RI, Ray RA, Daugherty JR, Griffin MR: Individual sulfonylureas and serious hypoglycaemia in older people. J. Am. Geriatr. Soc. 44, 751-755 (1996). (Pubitemid 26238715)
21. Tessier D, Dawson K, Tétreault JP, Bravo G, Meneilly GS: Glibenclamide vs gliclazide in Type 2 diabetes of the elderly. Diabet. Med. 11, 974-980 (1994). (Pubitemid 24375836)
22. Gold AE, MacLeod KM, Frier BM: Frequency of severe hypoglycaemia in patients with Type 1 diabetes with impaired awareness of hypoglycaemia. Diabetes Care 17, 697-702 (1994).
23. Warren R, Allen KV, Sommerfield AJ, Deary IJ, Frier BM: Acute hypoglycemia impairs nonverbal intelligence. Diabetes Care 27, 1447-1448 (2004).
24. Jaap AJ, Jones GC, McCrimmon RJ, Deary IJ, Frier BM: Perceived symptoms of hypoglycaemia in elderly Type 2 diabetic patients treated with insulin. Diabet. Med. 15, 398-401 (1998). (Pubitemid 28197108)
25. McAulay V, Deary IJ, Frier BM: Symptoms of hypoglycaemia in people with diabetes. Diabet. Med. 18, 690-705 (2001). (Pubitemid 32955520)
26. Meneilly GS, Cheung E, Tuokko H: Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 43, 403-410 (1994). (Pubitemid 24064247)
27. Segel SA, Paramore DS, Cryer PE: Hypoglycemia-associated autonomic failure in advanced Type 2 diabetes. Diabetes 51, 724-733 (2002). (Pubitemid 34760182)
28. Miller ME, Bonds DE, Gerstein HC et al.: The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 304, 5444-5456 (2010).
29. Riddle MC, Ambrosius WT, Brillon DJ et al.: Epidemiological relationships between A1c and all-cause mortality during a median 3.4 year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 33, 983-990 (2010).
30. Zoungas S, Patel A, Chalmers J et al.: Severe hypoglycaemia and risks of vascular events and death. N. Engl. J. Med. 262, 1410-1418 (2010).
31. Stewart R, Liolitsa D: Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet. Med. 16, 93-112 (1999).
32. Biessels GJ, Stackenborg S, Brunner E, Brayne C, Scheltens P: Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 5, 64-74 (2006). (Pubitemid 41790697)
33. Van den Berg E, Kloppenborg RP, Kessels RP, Kappelle LJ, Biessels GJ: Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition. Biochim. Biophys. Acta 1792, 470-481 (2009).
34. Tiehuis AM, Mali WP, van Raamt AF et al.: Cognitive dysfunction and its clinical and radiological determinants in patients with symptomatic arterial disease and diabetes. J. Neurol. Sci. 283, 170-174 (2009).
35. Alafuzoff I, Aho L, Helisalmi S, Mannermaa A, Soininen H: b-amyloid deposition in brains of subjects with diabetes. Neuropathol. Appl. Neurobiol. 35, 60-68 (2009).
36. Ryan CM, Freed MI, Rood JA, Cobitz AR, Waterhouse BR, Strachan MW: Improving metabolic control leads to better working memory in adults with Type 2 diabetes. Diabetes Care 29, 345-351 (2006). (Pubitemid 44106516)
37. Thompson CS, Hakim AM: Living beyond our physiological means: small vessel disease of the brain is an expression of systemic failure in arteriolar function: a unifying hypothesis. Stroke 40, e322-e330 (2009).
38. De Galan BE, Zoungas S, Chalmers J et al.: Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with Type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia 52, 2328-2336 (2009).
39. Kim J, Basak JM, Holtzman DM: The role of apolipoprotein E in Alzheimers disease. Neuron 63, 287-303 (2009).
40. Dore GA, Elias MF, Robbins MA, Elias PK, Nagy Z: Presence of the APOE E4 allele modifies the relationship between Type 2 diabetes and cognitive performance: the Maine-Syracuse study. Diabetologia 52, 2551-2560 (2009).
41. Sinclair AJ, Girling AJ, Bayer AL: Cognitive dysfunction in older subjects with diabetes mellitus: impact on diabetes self-management and use of care services. All Wales Research into Elderly (AWARE) study. Diabetes Res. Clin. Pract. 50, 203-212 (2000).
42. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA: Dose-response relation between sulfonylurea drugs and mortality in Type 2 diabetes mellitus: a population-based cohort study. CMAJ 174, 169-174 (2006). (Pubitemid 43166269)
43. UK Prospective Diabetes Study (UKPDS): Group effects of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 352, 854-865 (1998).
44. Evans JM, Ogston SA, Emslie-Smith A, Morris AD: Risk of mortality and adverse cardiovascular outcomes in Type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49, 930-936 (2006).
45. Pilmore HL: Review: metformin: potential benefits and use in chronic kidney diseas. Nephrology 15, 412-418 (2010).
46. Khurana R, Malik IS: Meformin: safety in cardiac patients. Heart 96, 99-102 (2010).
47. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI: Effects of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation 106, 679-684 (2002). (Pubitemid 34851926)
48. Masoudi PA, Wang Y, Inzucchi SE et al.: Metformin and thiazolidinedion use in Medicare patients with heart failure. JAMA 290, 81-85 (2003). (Pubitemid 37432869)
49. Nesto RW, Bell D, Bonow RO et al.: Thiazolidinedione use, fluid retention, and congestive heart failure. Diabetes Care 27, 256-263 (2004).
50. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007). (Pubitemid 46919772)
51. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE et al.: Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304, 411-418 (2010).
52. Drucker DJ, Sherman SL, Gorelick FS, Bergenstat RM, Sherwin RS, Buse JB: Incretin-based therapies for the treatment of Type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 22, 428-422 (2010).
53. European Diabetes Working Party for Older People 2001-2004: Clinical Guidelines for Type 2 diabetes mellitus www.euroage-diabetes.com